Innate Pharma S.A.
EPA:IPH.PA
1.61 (EUR) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Innate Pharma S.A. |
Symbool | IPH.PA |
Munteenheid | EUR |
Prijs | 1.61 |
Beurswaarde | 130,327,608 |
Dividendpercentage | 0% |
52-weken bereik | 1.59 - 2.8 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mondher Mahjoubi M.D. |
Website | https://www.innate-pharma.com |
An error occurred while fetching data.
Over Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)